Enveda raises $311M for nature-derived AI drugs

🔥 What happened Enveda closed a $311M Series E at a $2B valuation, led by Catalio Capital Management. The round doubles the biotech's valuation from just 12 months ago. 💡 Why it matters The startup uses AI to mine plants and microbes for drugs instead of synthesizing them from scratch. Two candidates are already in human trials: one for severe skin conditions, one to sustain weight loss after stopping GLP-1s. ⚡ Our take While other AI-biotechs are still chasing benchmarks, Enveda is already testing in humans. Nature-derived discovery could be the sleeper lever in AI pharma — if regulators buy it.